Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
221 participants
INTERVENTIONAL
2019-02-04
2023-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes
NCT03612960
Nicotine Withdrawal Symptoms and Smoking Relapse
NCT01511614
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
NCT01928758
Medicinal Nicotine for Preventing Stress Induced Craving and Withdrawal Symptoms
NCT01522963
Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
NCT00136838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Condition 1
Cigarette 1
Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Patch 1
A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Condition 2
Cigarette 2
Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Patch 1
A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Condition 3
Cigarette 1
Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Patch 2
A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Condition 4
Cigarette 2
Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Patch 2
A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cigarette 1
Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Cigarette 2
Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Patch 1
A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Patch 2
A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Daily smoking at least 2 years
Exclusion Criteria
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Illinois Institute of Technology
OTHER
University of Southern California
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adam Leventhal
Professor of Preventive Medicine and Psychology, Director of the Health, Emotion, and Addiction Laboratory
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam M Leventhal, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Southern California
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Southern California
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
28IR-0063
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.